PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR
Top Cited Papers
Open Access
- 1 March 2007
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 117 (3) , 730-738
- https://doi.org/10.1172/jci28984
Abstract
The receptor tyrosine kinase/PI3K/Akt/mammalian target of rapamycin (RTK/PI3K/Akt/mTOR) pathway is frequently altered in tumors. Inactivating mutations of either the TSC1 or the TSC2 tumor-suppressor genes cause tuberous sclerosis complex (TSC), a benign tumor syndrome in which there is both hyperactivation of mTOR and inhibition of RTK/PI3K/Akt signaling, partially due to reduced PDGFR expression. We report here that activation of PI3K or Akt, or deletion of phosphatase and tensin homolog (PTEN) in mouse embryonic fibroblasts (MEFs) also suppresses PDGFR expression. This was a direct effect of mTOR activation, since rapamycin restored PDGFR expression and PDGF-sensitive Akt activation in Tsc1–/– and Tsc2–/– cells. Akt activation in response to EGF in Tsc2–/– cells was also reduced. Furthermore, Akt activation in response to each of EGF, IGF, and PMA was reduced in cells lacking both PDGFRα and PDGFRβ, implying a role for PDGFR in transmission of growth signals downstream of these stimuli. Consistent with the reduction in PI3K/Akt signaling, in a nude mouse model both Tsc1–/– and Tsc2–/– cells had reduced tumorigenic potential in comparison to control cells, which was enhanced by expression of either active Akt or PDGFRβ. In conclusion, PDGFR is a major target of negative feedback regulation in cells with activated mTOR, which limits the growth potential of TSC tumors.Keywords
This publication has 50 references indexed in Scilit:
- Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioningThe Journal of cell biology, 2006
- Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesisNature Reviews Cancer, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- The Akt-mTOR tango and its relevance to cancerPublished by Elsevier ,2005
- Mechanism of Divergent Growth Factor Effects in Mesenchymal Stem Cell DifferentiationScience, 2005
- Efficacy of a rapamycin analog (CCI‐779) and IFN‐γ in tuberous sclerosis mouse modelsGenes, Chromosomes and Cancer, 2004
- Estrogen-induced Smooth Muscle Cell Growth Is Regulated by Tuberin and Associated with Altered Activation of Platelet-derived Growth Factor Receptor-β and ERK-1/2Journal of Biological Chemistry, 2004
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- p73 Independent of c-Myc Represses Transcription of Platelet-derived Growth Factor β-Receptor through Interaction with NF-YJournal of Biological Chemistry, 2002
- The biology of platelet-derived growth factorCell, 1986